Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumours, Including Central Nervous System Tumours

Official Title

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumours, Including CNS Tumours

Summary:

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent/refractory solid tumours. Phase 2, utilizing Simon's optimal 2-stage design, will be conducted to estimate the antitumour activity of lenvatinib in combination with everolimus in pediatric participants with selected recurrent/refractory solid tumours including Ewing sarcoma/peripheral primitive neuroectodermal tumour (pPNET), rhabdomyosarcoma, and high grade glioma (HGG) using objective response rate (ORR) at Week 16 as the outcome measure.

Trial Description

Primary Outcome:

  • Maximum tolerated dose (MTD) of lenvatinib in combination with everolimus: Phase 1
  • Recommended Phase 2 dose (RP2D) of lenvatinib in combination with everolimus: Phase 1
  • Number of participants with any treatment-emergent (TE) serious adverse event (SAE) in Phase 1, as a measure of the safety and toxicity of lenvatinib in combination with everolimus
  • Number of participants with any TE adverse event (TEAE) in Phase 1, as a measure of the safety and toxicity of lenvatinib in combination with everolimus
  • Overall Response Rate (ORR) at Week 16 for Phase 2
Secondary Outcome:
  • ORR at the time of data cutoff: Phase 1
  • ORR at the time of data cutoff: Phase 2
  • Disease Control Rate (DCR): Phase 1
  • DCR: Phase 2
  • Clinical Benefit Rate (CBR): Phase 1
  • CBR: Phase 2
  • Duration of Response (DOR): Phase 1
  • DOR: Phase 2
  • Area under the plasma concentration time course profile (AUC): Phase 1
  • AUC: Phase 2
  • Maximum observed concentration (Cmax): Phase 1
  • Cmax: Phase 2
  • Time from dosing to the maximum observed concentration (Tmax): Phase 1
  • Tmax: Phase 2
  • Number of participants with any TE SAE in Phase 2, as a measure of the safety and toxicity of lenvatinib in combination with everolimus
  • Number of participants with any TEAE in Phase 2, as a measure of the safety and toxicity of lenvatinib in combination with everolimus

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society